Cantor Fitzgerald Reiterates Buy Rating on Quince Therapeutics
Cantor Fitzgerald maintains its buy rating for Quince Therapeutics, Inc. with a $4.00 price target, a 315.11% upside from the current price.
Key Points
- Cantor Fitzgerald reiterated its buy rating on Quince Therapeutics, Inc. with a price target of $4.00 on June 23, 2026.
- Cantor Fitzgerald's $4 price target implies 315.11% upside from Quince Therapeutics, Inc.'s ($QNCX) current $0.96 share price.
- Shares of NasdaqGS:QNCX traded near $0.95 on Tuesday, with a market cap of about $18.1 million.
- Recent insider activity at Quince Therapeutics includes significant share purchases by key executives.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Cantor Fitzgerald has reiterated its buy rating for Quince Therapeutics, Inc. (NasdaqGS:QNCX), setting a price target of $4.00. This update came on June 23, 2026, as analyst Olivia Brayer Saunders expressed confidence in the biotechnology company's prospects.
Cantor Fitzgerald vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Quince Therapeutics, Inc. Stock Down 97.1%
Shares of Quince Therapeutics traded near $0.95 on Tuesday. The company's market cap stands at approximately $18.1 million. Quince Therapeutics has no meaningful forward P/E ratio due to its lack of profitability, and the stock has a beta of 1.373, indicating moderate volatility. Its 52-week range spans from $0.79 to $45.50, with a 50-day moving average of $1.17 and a 200-day moving average of $13.04. The company maintains a current ratio of 2.917 and a quick ratio of 2.819, with a debt-to-equity ratio of 2.591.
$QNCX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Quince Therapeutics, Inc.
Recent insider activity at Quince Therapeutics reveals notable transactions. On June 11, 2026, insiders Christopher Senner and David Lamond each purchased 2,700 shares. Brigette Roberts, the Chief Corporate Affairs Officer, acquired over 9.8 million shares on May 18, 2026. Earlier in the year, on January 23, 2026, Brendan Hannah, serving as CBO, COO, and CCO, sold 365,000 shares, while Charles Ryan, the President, bought 200,000 shares.
Analysts Set New Price Targets
On June 23, 2026, Cantor Fitzgerald reiterated its buy rating for Quince Therapeutics with a $4.00 price target. Previously, D. Boral Capital maintained its buy rating with a $5.00 target on January 29, 2026. Analysts generally maintain a positive outlook on the stock, with a consensus buy recommendation and an average target price, reflecting optimism about the company's future.
About Quince Therapeutics
Quince Therapeutics, Inc. is a biotechnology firm based in South San Francisco, California. The company focuses on developing treatments for rare and debilitating diseases. Its lead candidate, eDSP, is in Phase 3 trials for treating a rare pediatric neurodegenerative disease. Quince also utilizes its AIDE technology platform, which combines drug and device technology to encapsulate drugs in a patient's red blood cells. The company was formerly known as Cortexyme, Inc. and rebranded in August 2022.
Bottom Line
Cantor Fitzgerald's reiteration of a buy rating with a $4.00 target highlights confidence in Quince Therapeutics' future potential. Investors track such ratings closely for insights into the company's prospects. As with all 13F filings and analyst ratings, it's important to remember that these are backward-looking and may not reflect current market conditions.
Get Quince Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $QNCX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.